[stock_market_widget type=”card” template=”basic2″ assets=”OSTX” realtime=”true” api=”yahoo-finance”]
Rare pediatric bone cancers rarely draw much attention from investors, yet a small clinical stage company working out of New York and Rockville, Maryland has just published data that could change that calculation. OS Therapies, Inc. (NYSE American: OSTX) is a gene edited, Listeria based cancer immunotherapy developer, and its lead candidate, OST-HER2, is aimed at osteosarcoma, the most common bone cancer diagnosed in children and young adults, along with related solid tumors.
Osteosarcoma that spreads to the lungs after surgery has long lacked an approved targeted treatment, and roughly half of patients face this recurrence at some point after their tumor is removed and chemotherapy is completed. For families and physicians dealing with this disease, the absence of new options for four decades has made any credible clinical signal worth watching closely. OST-HER2 works by using Listeria bacteria to stimulate an immune response against the HER2 protein, and it is engineered so that a tumor only needs to carry one of three targeted mutations for the intended immune reaction to occur. The candidate has already received Orphan Drug Designation, Fast Track Designation and Rare Pediatric Disease Designation from the FDA, along with Orphan Drug Designation, Fast Track Designation and Advanced Therapy Medicinal Product status from European regulators.
The company reported interim results from its Phase 2b trial studying OST-HER2 in patients with fully resected, pulmonary metastatic osteosarcoma. Among 41 enrolled patients, those treated with OST-HER2 reached a three-year overall survival rate of 71.2%, compared with 45.8% in a combined historical control group used for regulatory discussions. The difference was statistically significant, with a p value of 0.002. Two patients had not yet reached the three-year mark at the time of reporting, and six were lost to follow up during the study.
Those numbers matter because they support the next steps in the company’s regulatory strategy. OS Therapies intends to submit a Biologics License Application to the U.S. Food and Drug Administration under its Accelerated Approval Program, along with Conditional Marketing Authorization Applications in the United Kingdom, the European Union and Australia. The company is targeting the fourth quarter of 2026 for these submissions, with a goal of making OST-HER2 commercially available to patients in 2027.
Clinical progress alone rarely funds late-stage drug development, so the company also disclosed new financing news alongside the survival data. OS Therapies received $3.15 million in Value Added Tax refunds through its United Kingdom subsidiary and confirmed eligibility for at least $7.2 million more in refundable VAT and research and development tax credits. Management has earmarked these funds for the initiation of a confirmatory Phase 3 trial in the United Kingdom, a study that regulators require before they will act on the pending applications. That trial is expected to open only in the United Kingdom at first, since the MHRA has agreed to let the company use existing Phase 2 drug product to begin dosing rather than waiting on a new manufacturing run.
There is another financial angle worth understanding. Because OST-HER2 carries Rare Pediatric Disease Designation, a U.S. approval would make OS Therapies eligible for a transferable Priority Review Voucher, a credential that lets its holder jump to the front of the FDA review line or sell that right to another company. The most recent voucher of this kind changed hands in August 2026 for $220 million, though the company has cautioned that a future sale, if one occurs, may not command a similar price. Beyond osteosarcoma, OS Therapies is also developing an antibody drug conjugate platform and has completed dosing in an early prostate cancer study, adding some diversification to the pipeline.
A statistically significant survival benefit in a rare cancer with no approved targeted therapy is the kind of result that can shift how a company is valued, particularly one with a market capitalization under $100 million. The path from an interim readout to an approval remains long, and outcomes in accelerated review programs are never guaranteed. Still, a clear efficacy signal, active engagement with regulators across four jurisdictions, and freshly secured non dilutive funding give OS Therapies a clearer runway toward its stated 2027 commercialization goal than it had before this announcement.
